Real-World Data of Patients with BRAF V600E-Mutated Metastatic Colorectal Cancer Treated with Trifluridine/Tipiracil
Patients with <i>BRAF</i> mutant mCRC achieved modest benefits with FTD-TPI; however, patients with GPC and ECOG 0 achieved longer OS compared with those with PPC or ECOG 1-2, thus warranting further exploration in prospective cohorts.
Authors
- Iosune Baraibar (ORCID: https://orcid.org/0000-0002-3500-9641)
- Josep M. Tabernero (ORCID: https://orcid.org/0000-0002-2495-8139)
- N. Saoudi Gonzalez (ORCID: https://orcid.org/0000-0001-6044-1703)
- Eduardo García‐Galea (ORCID: https://orcid.org/0000-0003-4699-0786)
- Adriana Alcaráz (ORCID: https://orcid.org/0009-0002-5976-3312)
- Vicente Alonso (ORCID: https://orcid.org/0000-0001-8114-0168)
- Francesc Salvà (ORCID: https://orcid.org/0000-0001-9240-4907)
- Francesca Balconi
- Marta Rodríguez (ORCID: https://orcid.org/0000-0003-1935-0951)
- R. Comas (ORCID: https://orcid.org/0000-0003-4115-5095)
- Javier Ros (ORCID: https://orcid.org/0000-0002-8137-5415)
- Giulia Martini (ORCID: https://orcid.org/0000-0003-4093-2681)
- Elena Élez
- José María Ucha
- Pablo Gómez
- Ariadna García
Institutions
- University of Cagliari (IT)
- University of Campania "Luigi Vanvitelli" (IT)
- Hospital Universitario Miguel Servet (ES)
- Vall d'Hebron Hospital Universitari (ES)
- Vall d'Hebron Institute of Oncology (ES)
Publication Details
- Journal
- Cancers
- Published
- 2024-12-12
- DOI
- https://doi.org/10.3390/cancers16244140
- Citations
- 1
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Celgene
- Array BioPharma
- Taiho Pharmaceutical
- Exelixis
- Les Laboratories Pierre Fabre
- BeiGene
- NuCana
- Seagen
- Servier
- Novartis Farmacéutica
- PharmaMar
- Menarini Group
- Genentech
- Takeda Oncology
- Daiichi Sankyo Europe
- Cilag